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ALK-positive, advanced NSCLC in Argentina. Methods: A budget impact model 
we developed to evaluate two separate scenarios from a payer’s perspective. The 
model compared scenarios with and without crizotinib. In the crizotinib scenario all 
patients testing positive for the ALK mutation were given crizotinib. Comparators 
were platin-containing regimens (ex pemetrexed), platin/pemetrexed, erlotinib/gefi-
tinib, and crizotinib. Epidemiology, market basket, adverse event costs, and drug 
costs were informed through ten local physician questionnaires and published 
literature. The survey was administered to oncologists in six different private and 
public hospitals of varying sizes and locations in Argentina. Costs are in 2013 USD 
(1 USD = 5.88 ARS). Results: Considering the population of Argentina (42,610,981) 
and applying age based incidence rates, the number of lung cancer patients was 
estimated to be 12,139. Of those patients 82.5% were estimated to be have metastatic 
NSCLC and 74% were likely to be treated, leaving 7,411 treated patients in the model. 
The estimated one-year cost for treating these patients without crizotinib was esti-
mated to be $205,874,409. In the scenario including crizotinib, 154 patients (market 
uptake of 2.08%) were taken from other regimens and given crizotinib resulting in an 
estimated one-year cost of $224,651,145. The incremental total cost between these 
scenarios was $18,776,736 while the incremental costs per ALK+ patient and per 
member were $211 and $.04 respectively. These results were robust under standard 
parameter estimate variations. ConClusions: Adding crizotinib as a treatment 
option may have an acceptable budget impact under standard practices.
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Budgetary ImPaCt of oral ChemotheraPy IN BrazIl: a real World 
data aNalysIs from the PrIvate Payers’ PersPeCtIve
Clark O.A.C., Castro A.P., Alves A.F., Goes L., Borges L.
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objeCtives: In Brazil, health insurance companies (HIC) must, according to the law, 
offer coverage for intravenous (IVChem) antineoplastic drugs. The obligation to pay 
for oral drugs (OChem) was effective only after January 2014. Our goal was to evaluate 
the incremental costs and budgetary impact of the incorporation of OChem, using 
real world data, from the private payers’ perspective. Methods: During one year (Jun 
2012-mai 2013) we prospectively collected data on chemotherapy usage in 25 HIC, with 
a population of 3 million people from different regions in Brazil. First we calculated 
the costs of IVChem actually used. After that, we identified which patients would have 
formal indication for OChem either as a substitutive treatment or in association with 
IVChem. Then, we calculated the costs associated with this intervention. Later, the 
budgetary impact of using OChem for the eligible patients was calculated. Only drug 
acquisition costs were taken into account. We analyzed two scenarios: one with a 
total substitution of IVChem for OChem, when OChen treatment was less expensive 
than IVChem and another, using a “worst case scenario” approach, were OChem 
was used only in cases where it added costs. Results: During the one-year period, 
2,104 patients that received intravenous chemotherapy also had formal indication to 
receive OChem. If OChem had been used, in a rational protocol-based manner, there 
would have been an economy of R$ 0,10 (US$ 0,42) per HIC user per month. In the 
worst-case scenario, the incremental cost would be an additional R$ 0,39 (US$ 0,16) 
per HIC user per month. ConClusions: The budgetary impact secondary to OChem 
adoption may vary from decreasing costs to increasing them; depending on how they 
are used and to which patient they are prescribed. HIC should pay close attention to 
the profile of use of OChem in order to avoid unnecessary costs.
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objeCtives: In a Phase III clinical trial (Von Hoff, NEJM 2013) albumin-bound 
paclitaxel (nab-P) plus gemcitabine (nab-P/G) significantly improved median over-
all survival (OS) in first-line metastatic pancreatic cancer (1LmPanc) patients vs. 
gemcitabine (G) alone (8.7 vs. 6.6 months, hazard ratio 0.72, P< 0.001). The objective 
of this analysis is to estimate the budget impact of adding nab-P/G for 1LmPanc 
treatment at a US health plan. Methods: A budget impact model was built to 
estimate 1LmPanc costs for nab-P/G, G, Erlotinib + Gemcitabine (EG), Other G com-
binations (OG), and FOLFIRINOX (F), from a US health plan perspective in 2013 US 
dollars. Inputs for drug, administration, G-CSF, and adverse events were derived 
from prescribing information, publications, Medicare reimbursement rates, and 
other public sources. Sensitivity analysis assessed utilization mixes and elderly 
populations. Results: A 1,000,000-member health plan mirroring the US popula-
tion age mix would have 70 patients with 1LmPanc annually. The model assumed 
equal proportions of G, EG, OG, and F (25% of patients each) at baseline, and equal 
use (20% each) after nab-P/G 1LmPanc approval. Total course of therapy costs were 
G $2,634, EG $22,555, OG $10,840, F $39,437. Baseline total mPanc costs were $1.3 
million, or $0.11 per member per month (PMPM). Adding nab-P/G at $29,096 per 
course of therapy added $142,610, or $0.01 PMPM, to the baseline. In a sensitivity 
analysis with 50% of patients using nab-P/G, incremental cost was $0.03 PMPM. For 
a health plan population age 65-79, baseline cost of $0.48 PMPM rose $0.05 PMPM 
from nab-P/G. If only 70% of 1LmPanc patients received drug therapy, costs from nab-
P/G rose $0.01 from $0.08 PMPM at baseline. ConClusions: The budget impact of 
adding albumin-bound paclitaxel plus gemcitabine for a US health plan’s first-line 
metastatic pancreatic cancer patients was estimated at $0.01 PMPM; the impact 
was consistent across several sensitivity analyses.
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from peer reviewed literature. A multivariate sensitivity analysis using a Monte Carlo 
simulation was completed to ensure scientific rigour. Results: VATS lobectomies 
are associated with higher procedural costs, but this is offset by a shorter length of 
stay and a lower postoperative complication rate. The model establishes that for a 
Canadian hospital performing 150 lobectomies increasing the proportion of VATS 
cases from 25% to 75% allows for a potential cost savings of CAD $226,066.01 annu-
ally. ConClusions: In a Canadian hospital, VATS lobectomy is a more cost-effective 
procedure than open lobectomy for early stage lung cancer.
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objeCtives: Radium-223, an intravenously injected radioactive agent, is a new 
therapeutic option for CRPC patients with symptomatic bone metastases and no 
known visceral metastatic disease. This budget impact model (BIM) was developed 
from a United States (US) payer perspective to estimate the economic impact of 
adding radium-223 to current treatment options in this population. Methods: An 
Excel-based BIM evaluated costs of treating CRPC with symptomatic bone metas-
tases and no known visceral metastatic disease with available treatment options 
(chemotherapies, radionuclides, and oral antiandrogens) in a health plan with and 
without radium-223. One-year incremental costs were estimated for a hypothetical 
health plan with 1 million members. The prevalence of metastatic CRPC (mCRPC) 
patients was obtained from the national registry and published literature. Cost of 
therapy was obtained from Medicare average sales prices (ASP). Assumptions of out-
patient administration and laboratory utilization were derived from product-specific 
package inserts with costs transformed into costs per 4 weeks based on indicated 
dosing. Associated costs were derived from the Centers for Medicare & Medicaid 
Services (CMS) Physician Fee Schedule. Results: An estimated 220 patients were 
eligible for treatment with radium-223. Radium-223 was assumed to adopt 6.4% of 
the market in year 1 with equiproportional pull from available treatment options; 
a cost of $11,500 per 28-day cycle was assumed. In this base-case scenario, costs 
rose 1.7% ($208,755) or $0.02 per member per month (PMPM) compared to a health 
plan without radium-223. Sensitivity analyses, varying default inputs ± 10%, showed 
that results were robust, with greatest sensitivity to the number of radium-223 
doses ($0.01–$0.03 PMPM). Other key variables such as cycles of treatment, num-
ber of patients treated, and market share resulted in no change to PMPM budget 
impact. ConClusions: Economic modeling indicates that adding radium-223 to a 
health plan’s formulary minimally increases the PMPM cost by $0.02.
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objeCtives: Life Technologies has developed a 14-gene molecular assay (PervenioTM 
Lung RS) that provides mortality risk stratification in resected early-stage non-
squamous NSCLC. The test classifies patients as low, intermediate, or high-risk 
(for death), informing decisions about adjuvant chemotherapy use. Accordingly, 
high-risk patients may benefit from chemotherapy, and low-risk patients can avoid 
chemotherapy-associated morbidity and costs. Our objective was to estimate the 
budget impact of covering the assay in hypothetical commercial and Medicare 
health plans. Methods: We developed a Markov model to estimate costs before 
and after coverage of the 14-gene RS in commercial (age < 65) and Medicare (age 
65+) health plans with 1 million enrollees. Health plan age distributions and disease 
incidence were derived from the U.S. census and SEER, respectively. Risk-group 
classification was based on 14-gene RS clinical studies, and chemotherapy uptake 
was based on a study of pre/post testing recommendations from 58 surgeons/
oncologists. Included costs were those of the assay, chemotherapy with NCCN-
recommended regimens, monitoring, post-recurrence care, and adverse events. We 
calculated the total and per-member per-month (PMPM) 1-year budget impact of 
adding coverage for the 14-gene RS, and evaluated uncertainty using one-way sensi-
tivity analyses. Results: The 1-year budget impact of covering the 14-gene RS assay 
in commercial and Medicare health plans with 1 million members is expected to be 
$24,200 (PMPM= $0.002) and $178,800 (PMPM= $0.015), respectively. The most influen-
tial parameters were the proportion of high-risk patients receiving chemotherapy, 
the chemotherapy recurrence hazard ratio, and the proportion of patients receiving 
initial surgical treatment. ConClusions: Our analysis suggests that covering the 
14-gene RS assay is expected to increase chemotherapy use, decrease recurrences, 
and result in a small net increase in PMPM cost in commercial and Medicare health 
plans. These outcomes indicate that the assay has the potential to provide positive 
health outcomes for health plan members at a reasonable cost.
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objeCtives: Non-small cell lung cancer (NSCLC) accounts for the majority of lung 
cancer cases and a high number of these patients have metastatic cancer at the time 
of diagnosis. The ALK mutation is only found in about 4% of NSCLC patients. The 
study aims to evaluate the budgetary impact of adding crizotinib for patients with 
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lung cancer (NSCLC). Methods: A Markov Model was developed to evaluate the 
disease progression of a cohort of patients with ALK +ve advanced NSCLC in a three 
year period, that will be treated with Crizotinib. The model compares scenarios With 
and Without Crizotinib. The difference in total costs is the net impact of Crizotinib 
on the health care budget. Local epidemiologic data was used. Costs were estimated 
from Panama Public Health System ($US, 2012) and included costs of treatment, 
administration and monitoring, palliative care, and severe adverse events. The base 
case scenario assumes 100% testing rate for ALK in incident patients and 100% 
market share for crizotinib in ALK+Ve advanced NSCLC patients. Sensitivity analy-
ses were performed for 80-100% market share [3] Results: In a three year period, 
23 patients received Crizotinib (from a cohort of 609 advanced NSCLC patients). 
Cost related to drug acquisition and management of adverse in a world “With” and 
“Without” Crizotinib during three years are $13.426.918 and $12.670.537 respec-
tively which represents $756.381 of budget impact associated with the insertion of 
Crizotinib in the market, however it shows savings in terms of drug administration, 
monitoring costs and progression cost, with an estimated of $471.952 (Difference 
between the two scenarios of $3.931.399 and $4.403.351). Net budget Impact for the 
three year period is $284.428, which represents for the first year ($48.997, $0.0018 
per patient-per month [PMPM]) approximately 0.00289% of Panama’s Total Public 
Health Expenditure (2011). [4] If the Crizotinib market share is assumed to be 80%, 
the net impact was $92.996. ConClusions: Crizotinib for the treatment of ALK+ 
NSCLC patients has a minimal incremental budget impact on the overall expendi-
ture within the Panama Health System.
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a Budget ImPaCt model for the INtroduCtIoN of BevaCIzumaB for 
the treatmeNt of NeWly dIagNosed glIoBlastoma multIforme IN the 
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objeCtives: Newly diagnosed glioblastoma multiforme (GBM) is associated with 
poor prognosis and limited treatment options. The placebo controlled AVAglio 
study demonstrated that the addition of bevacizumab to radiotherapy (RT) plus 
temozolomide (TMZ) improves progression-free survival (PFS) by 4.4 months, and 
maintains health-related quality of life in patients with newly diagnosed GBM. A 
budget impact model (BIM) has been developed to calculate the costs associated 
with the introduction of bevacizumab for the treatment of newly diagnosed GBM in 
the UK. Methods: The BIM is based on UK epidemiological and resource data and 
compares a base case in which all eligible patients are treated with radiotherapy + 
TMZ only with a scenario in which bevacizumab is introduced with increased uptake 
over a three year period. The model combines drug, adverse events, and administra-
tive costs to estimate the total cost of treating the eligible patient population in the 
UK using published sources converted into £ (2013). Results: The BIM estimates 
that, in year 1, with an expected 10% uptake of bevacizumab, the total cost would be 
£5,619,457, £11,463,690 in year 2, with an expected uptake of 20%, and £16,688,655 
in year 3, with an expected uptake of 30%. When these costs are considered in the 
context of the total oncology costs for the UK in 2013, the budget impact of the intro-
duction of bevacizumab in years 1, 2 and 3 is 0.08 %, 0.17% and 0.25%, respectively. 
When the costs related to bevacizumab alone are considered in the context of the 
total oncology drug budget for the UK in 2013, the costs for bevacizumab for years 
1, 2 and 3 are 0.42%, 0.95 % and 1.43% of the budget, respectively. ConClusions: 
The introduction of bevacizumab for the treatment of newly diagnosed GBM in the 
UK is associated with a low budget impact.
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Budget ImPaCt aNalysIs of BevaCIzumaB Plus ChemotheraPy versus 
BevaCIzumaB aNd aNtI-egfr WIth ChemotheraPy for fIrst aNd 
seCoNd lINe treatmeNt of metastatIC ColoreCtal CaNCer IN russIaN 
federatIoN
Yagudina R., Kulikov A., Komarov I.
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objeCtives: To estimate the budget impact of bevacizumab plus chemotherapy 
for first and second line metastatic colorectal cancer (mCRC) treatment compared 
with chemotherapy with anti-EGFR for first line and bevacizumab plus chemo-
therapy for second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with mCRC 
and resulting follow-up costs were calculated using general tariff agreement of 
Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab plus chemotherapy 
for first and second line in the mCRC therapy provided cost saving benefits com-
pared with chemotherapy with anti-EGFR for first line and bevacizumab plus 
chemotherapy for second line. Total health care costs of mCRC therapy were 
approximately 1 145 826 RUB (38 194 $) in bevacizumab+FOLFOX 1 line therapy, 
544 905 RUB (18 164 $) in bevacizumab+FOLFIRI 2 line therapy and 2 957 187 RUB 
(98 573 $) in panitumumab+FOLFOX4 1 line therapy, 872 226 RUB (29 074 $) in 
bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 2 138 681 RUB (71 289 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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objeCtives: To estimate the burden of disease and costs associated with smok-
ing in Colombia. Methods: Epidemiological data was retrieved from the National 
Administrative Department of Statistics (DANE), Integrated Information System 
on Social Protection (SISPRO) and National Survey of Substance abuse 2008 data-
bases. Costs are expressed in 2012 prices and were obtained from local studies and 
regional approximations. A micro-simulation first order Monte Carlo model was 
constructed, incorporating natural history, costs and quality of life of the most 
important diseases related with smoking: stroke, Coronary Heart Disease (CHD), 
Chronic Obstructive Pulmonary Disease (COPD), and lung cancer. The model was 
programmed in Excel (Microsoft Excel ® Office Professional Edition 2003) with Visual 
Basic ® Macros (Microsoft Visual Basic® 6.3). A software package was installed to 
improve the random number generator function in Excel®. Results: 15.9% of the 
total annual deaths in Colombia are attributable to smoking (6,776 heart disease, 
6,619 COPD, 3,544 lung cancer and 1,831 stroke). Smoking is responsible for 112,891 
hospital admission and it is estimated that 10,606 people are diagnosed annually 
with cancer caused by smoking. The direct health care costs associated with smok-
ing is USD$ 1.692 million dollars (USD$863,103,308 heart diseases, USD$442,619,734 
COPD, USD$ 170,000,285 lung cancer and USD$216,852,028 stroke). ConClusions: 
Smoking is directly responsible for the loss of 674.262 lives each year in Colombia 
and generates an annual direct health care cost of more than 4 billion Colombian 
pesos, equivalent to 0.6% of Colombian GDP and 10.5% of health care spending. 
These results could be useful for decision makers to reinforce public policies regard-
ing smoking cessation in Colombia.
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objeCtives: To estimate the budget impact of bevacizumab combinations in the 
metastatic colorectal cancer (mCRC) treatment and chemotherapy with anti-EGFR 
for first and second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with 
mCRC and resulting follow-up costs were calculated using general tariff agree-
ment of Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab treatment combinations 
in the mCRC therapy provided cost saving benefits compared with chemotherapy 
with anti-EGFR for first and second line therapy. Total health care costs of mCRC 
therapy were approximately 1 187 115 RUB (39 571 $) in bevacizumab+FOLFIRI 1 
line therapy, 662 242 RUB (22 075 $) in bevacizumab+CAPOX 2 line therapy and 2 
518 311 RUB (83 944 $) in cetuximab+FOLFIRI 1 line therapy, 872 226 RUB (29 074 $) 
in bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 1 541 181 RUB (51 373 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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ChroNIC myeloId leukemIa IN ColomBIa
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objeCtives: To analyze the budget impact of the use of nilotinib in first and second 
line chronic myeloid leukemia (CML), compared with imatinib and dasatinib, from 
the perspective of a third party payer in Colombia. Methods: A Markov model 
was developed with a 5-year time horizon simulating first and second line treat-
ment of CML patients, with treatment options including nilotinib, imatinib and 
dasatinib. 2013 incidence and prevalence figures were estimated from international 
data. Base case market share for each compound was obtained from public national 
medicines registry (Sismed) for the years 2012 – 2013. Resource utilization and costs 
of medicines, health care services and adverse events were estimated according to 
clinical trials data and local health care provider databases. The analysis estimated 
up to 80% market share for nilotinib in both lines. A univariate sensitivity analy-
sis was developed to identify the effect of individual parameter variation on final 
results. Results: Nilotinib inclusion as a first and second line treatment option 
for CML patients resulted in a cumulative impact of COP $14.961 million over 5 
years, corresponding to a 0.056% per capita premium (UPC) in the Colombian care 
health system. Year to year, the impact was calculated from COP $1,168 million to 
COP $6,588 million on the fifth year. The sensitivity analysis showed the costs of 
technologies, health care services and disease progression as the most relevant 
variables. ConClusions: The budget impact analysis showed that increasing the 
use of nilotinib both in first and second line treatment of CML patients poses a 
minimal impact on the Colombian health care system, within parameters similar 
to those used in 2012 for the inclusion of technologies in the benefit plan. Additional 
benefits in lower progression rates and potential increased survival may favor this 
technology to be reimbursed within the premium (UPC) in Colombia.
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objeCtives: The purpose of this model is to examine the budgetary impact of the 
decision to reimburse crizotinib for patients with ALK+ve advanced non-small-cell 
